Core Viewpoint - RBC Capital analyst Deane Dray raised the price target for 3M Company from $120 to $130 while maintaining an Underperform rating [1] Recent Earnings Results - 3M reported third-quarter adjusted sales of $6.3 billion, slightly above the consensus estimate of $6.255 billion [2] - Adjusted earnings per share increased by 10% year-over-year to $2.19, surpassing the Street estimate of $2.07 [2] - The company raised its 2025 adjusted EPS outlook to a range of $7.95-$8.05, compared to the prior range of $7.75-$8 and the consensus of $7.92 [2] - 3M now expects organic sales growth of over 2% for 2025, an increase from the previous estimate of approximately 2% [3] Analyst View - The analyst noted that 3M reported modest, broad-based operational results, highlighting stronger organic growth and successful new product launches [4] - The initial outlook for 2026/2027 is encouraging, projecting a macro environment similar to 2025, with core incrementals of 30%-40% and productivity offsetting various costs [4] - However, the analyst emphasized that the multi-billion-dollar PFAS litigation remains a significantly underappreciated risk, particularly concerning unaddressed claims [5] - The next key event will be determining the final number of cancer claimants for personal injury class actions, with estimates varying widely from an initial base of 14,000 claims [5] Price Action and Investment Options - 3M shares are down 0.23% at $166.26 at the time of publication [6] - Investors can gain exposure to 3M stock through ProShares Smart Materials ETF and PGIM Jennison Focused Value ETF [6]